DTIL · Precision BioSciences, Inc.

Current Thesis

Precision BioSciences’ hepatitis B gene-editing thesis depends on the year-end 2026 update reproducing its initial liver-biopsy result in additional patients before the market breaches the published $6.50 weekly-close boundary. The company’s 2026-08-06 update retained that clinical timetable; no subsequent clinical result was identified in the company release index reviewed on 2026-09-13. Company releases

The narrative is maturing — the mechanism headline dates to 2026-05-27, while the 2026-09-11 reference close was $7.17, below the $7.47 close recorded on 2026-09-04. This is an inference about the dated sequence of news and prices; participation data are missing. Replicated biopsy findings would challenge that classification by supplying new clinical evidence.

Bullish and bearish views on Precision BioSciences, Inc.

The model's bull view on Precision BioSciences, Inc. (DTIL), in brief: Direct evidence in liver tissue. On 2026-05-27, Precision reported a 1-log reduction in covalently closed circular DNA (cccDNA)-derived transcripts after two 0.4 mg/kg doses and described less than 1% of cccDNA remaining. These are company-reported measurements supporting the… The bear view: Safety requires fuller qualification. The 2026-05-27 release reported no dose-limiting toxicities, but also reported severe hypotension and two serious adverse events in a patient receiving 0.8 mg/kg, one treatment-related. Slower infusions and increased steroids were… Both cases follow in full.

Bull Case

• Direct evidence in liver tissue. On 2026-05-27, Precision reported a 1-log reduction in covalently closed circular DNA (cccDNA)-derived transcripts after two 0.4 mg/kg doses and described less than 1% of cccDNA remaining. These are company-reported measurements supporting the proposed mechanism; the biopsy sample is too small to establish reproducibility. Clinical release
• Blood markers support biological activity. At the 2026-05-04 cutoff, the company reported loss of detectable pregenomic RNA (pgRNA) in six patients with detectable pretreatment levels and hepatitis B surface antigen (HBsAg) declines in 15 patients. These observations do not establish durable cure after existing antiviral treatment stops. 2026-05-27 results
• Another program entered clinical testing. Precision announced first dosing in the FUNCTION-DMD trial for Duchenne muscular dystrophy on 2026-08-24. That establishes clinical execution for PBGENE-DMD; it supplies no evidence yet of patient benefit. Company announcement index

Bear Case

• Safety requires fuller qualification. The 2026-05-27 release reported no dose-limiting toxicities, but also reported severe hypotension and two serious adverse events in a patient receiving 0.8 mg/kg, one treatment-related. Slower infusions and increased steroids were introduced; absence of dose-limiting toxicity does not mean absence of serious harm. Clinical safety disclosure
• Runway includes prospective equity funding. The 2026-08-06 financial update reported $112.4 million in cash, equivalents and restricted cash at 2026-06-30. Management’s runway through 2028 included availability under its at-the-market equity facility; that financing assumption is distinct from cash already reported.
• Clinical replication remains unresolved. The 2026-05-27 biopsy headline rests on the initial patient result described above. Failure to reproduce cccDNA reduction in additional patients at the guided year-end update would invalidate the clinical extension of that finding.

Setup & Price Structure

The supplied adjusted market series records a $7.17 close on 2026-09-11, 22.7% below its $9.28 52-week high, alongside a positive 17.5% three-month price change. Its 14-period relative strength index (RSI) was 9.6 on that date. The snapshot shows weak recent momentum within a positive three-month comparison; it does not establish a rebound.

The $6.50 weekly-close threshold remains the research boundary published on 2026-09-05. The available snapshot does not independently establish that level as traded support. Moving-average values, volume, short interest and dated retail-participation measures are missing, so crowding cannot be determined. The equity facility described on 2026-08-06 establishes potential share supply, without demonstrating subsequent issuance into strength.

Catalyst Calendar (next 30 days)

For 2026-09-13 through 2026-10-13, no company-confirmed catalyst date was identified in the available announcements or event calendar. The calendar’s latest listed 2026 investor presentation was on 2026-06-03; that listing does not rule out an unscheduled announcement. Company event calendar

• ~2026-12-31, timing placeholder: The 2026-08-06 update guided additional PBGENE-HBV clinical results to year-end 2026. December 31 represents the end of that guidance window, not an announced presentation date. Additional biopsies are the test of replication; an update without them would leave the thesis unconfirmed. Quarterly update

What Would Change Our Mind

Loss of the published market boundary ends this setup: a weekly close below $6.50 constitutes price invalidation. Clinical confirmation requires additional patients showing cccDNA reduction by the end of the company’s 2026 guidance window without a treatment-limiting safety finding. Contrary biopsy results, a clinical hold, or the year-end window passing without replication would defeat that stated case.

The evidence supports low conviction because the initial biopsy sample cannot establish reproducibility, the 2026-05-27 disclosure contains serious safety events, and the 2026-09-11 price snapshot shows weak recent momentum.

Correlation Notes

This remains a single-company clinical setup. The 2026-09-13 research context supplies no established peer cluster or matched return series, so a measured correlation with gene-editing equities cannot be stated. The 2026-08-24 start of Precision’s own Duchenne trial broadens its clinical exposure, but does not independently validate the hepatitis B result.